Pharmaceuticals
Market Cap
₹103 ₹103 Cr.
P/E
13.90
PEG
0.80
PEG = P/E ÷ 5yr forward EPS CAGR
5yr forward EPS CAGR thesis · Base case

Thesis hinges on own-brand scale-up via wider B2B distribution and planned D2C expansion lifting its share of growth

Bull case requires faster own-brand conversion plus stronger third-party utilization; bear case is own-brand shortfall compounded by key-customer order cuts with no long-term contracts and single-facility dependence

Early confirmation comes from own-brand disclosure through FY28 alongside third-party run-rate and EBITDA margin discipline

Overview

Shareholder Break-up

Trend

  • 1y
  • 2y
  • 4y
  • 5y
  • 10y
  • Promoter
  • Mutual Funds
  • Insurance Companies
  • FII
  • DII-Others
  • Individual < 2 lac
  • Shares Pledged by Promoters(As a % of Total Promoter Holding)
  • Others

Detailed

FAQs on Himalaya Nutravedics India Ltd. Shareholdings

There is Insufficient data to gauge this.

There is Insufficient data to gauge this.

Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech